Roku reported its second quarterly earnings report ever, since becoming a publicly traded company. Andre Swanston, CEO of Tru Optik, an audience measurement and data management platform for OTT, was with us to share why he thinks Roku is positioned for success.
Swanston said the OTT space is "so wild" in terms of the growth in penetration and time spent. On top of that, he said most of that growth is on ad supported platforms, not services like Netflix. This bodes well for Roku because they are the only pure-play OTT company on the street, Swanston said.
Roku debuted a licensing program for smart audio devices and expects the first to ship this fall. They're going up against Amazon, Google, and Apple. Swanston said Roku has no strategic advantage for a smart speaker and does not anticipate it being a significant revenue generator.
Student loan borrowers have the ability to earn retirement funds pegged to their payments – and the company Summer might be bringing it to your workplace.
It might not be what investors want to hear… but bringing down inflation could mean interest rates stay higher for (even) longer. But it's not all downside.
President Joe Biden and Chinese President Xi Jinping have discussed Taiwan, artificial intelligence and security issues in a call meant to demonstrate a return to regular leader-to-leader dialogue between the two powers.
April is Earth month, and while the green revolution might feel far away, the founder of climate VC Siam Capital says it’s on it’s way, and, even better: it won't cost you more.
From snow in April to heatwaves in December, it’s hard to plan a trip in a climate change world. Startup Sensible Weather thinks weather-based travel reimbursements are the solution.
Between corporate debt and the widening gap between ‘the haves and the have nots,’ there are reasons to be cautious about the economy, even with interest rate cuts on their way.
If the A.I. hype hasn’t given you enough of a reason to be excited (and a little terrified), the CEO of Zapata AI says the next frontier is designing bridges or creating pharmaceutical drugs.
